UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2021~~2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39580

Immunome, Inc.

(Exact name of registrant as specified in its charter)

Delaware	77-0694340
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

665 Stockton Drive, Suite 300 Exton, PA	19341
(Address of principal executive offices)	(Zip Code)

(610) 321-3700

(Registrant’s telephone number, including area code)

Not applicable.

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		IMNM		The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒	Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were ~~11,814,230~~12,127,385 shares of the registrant’s common stock outstanding as of August ~~12, 2021.~~2, 2022.

Table of Contents

IMMUNOME, INC.

Quarterly Report on Form 10-Q for the Quarterly Period ended June 30, ~~2021~~2022

Table of Contents


		Page

	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	- Condensed Balance Sheets as of June 30, ~~2021~~2022 and December 31, ~~2020~~2021	3
	- Condensed Statements of Operations for the Three and Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021	4
	- Condensed Statements of Changes in ~~Convertible Preferred Stock and~~ Stockholders’ Equity ~~(Deficit)~~ for the Three and Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021	5
	- Condensed Statements of Cash Flows for the Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021	6
	- Notes to Condensed Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	1618
Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	2729
Item 4.	Controls and Procedures.	2730

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings.	2930
Item 1A.	Risk Factors.	2930
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	2930
Item 3.	Defaults Upon Senior Securities.	2930
Item 4.	Mine Safety Disclosures.	2930
Item 5.	Other Information.	2930
Item 6.	Exhibits.	3031

	SIGNATURES

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

IMMUNOME, INC.

Condensed Balance Sheets

(In thousands, except share data)

(unaudited)

June 30, 2021

December 31, 2020

Assets



Current assets:





Cash

$
59,829

$
39,766

Prepaid expenses and other current assets

2,986

3,128

Total current assets

62,815

42,894

Property and equipment, net

1,226

1,531

Restricted cash

100

100

Total assets

$
64,141

$
44,525

Liabilities and stockholders’ equity





Current liabilities:





Accounts payable

1,790

1,187

Accrued expenses and other current liabilities

1,687

1,372

Equipment loan payable

44

113

Current portion of long-term debt

—

366

Total current liabilities

3,521

3,038

Long-term debt, net of current portion

—

134

Deferred rent

3

8

Total liabilities

3,524

3,180

Commitments and contingencies (Note 6)





Stockholders’ equity:



Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2021 and December 31, 2020; 11,812,792 shares issued and outstanding at June 30, 2021; 10,634,245 shares issued and outstanding at December 31, 2020

1

1

Additional paid-in capital

124,149

95,738

Accumulated deficit

(63,533)

(54,394)

Total stockholders’ equity

60,617

41,345

Total liabilities and stockholders’ equity

$
64,141

$
44,525


	June 30, 2022		December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	34,649	$	49,229
Prepaid expenses and other current assets		2,949		7,409
Total current assets		37,598		56,638
Property and equipment, net		807		855
Operating right-of-use asset, net		182		—
Restricted cash		100		100
Deferred offering costs		332		332
Total assets	$	39,019	$	57,925
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	5,259	$	3,077
Accrued expenses and other current liabilities		3,359		6,651
Total current liabilities		8,618		9,728
Other long-term liabilities		124		12
Total liabilities		8,742		9,740
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 shares issued or outstanding at June 30, 2022 and December 31, 2021, respectively		—		—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,127,385 and 12,110,373 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		1		1
Additional paid-in capital		129,958		127,289
Accumulated deficit		(99,682)		(79,105)
Total stockholders’ equity		30,277		48,185
Total liabilities and stockholders’ equity	$	39,019	$	57,925

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Statements of Operations

(In thousands, except share and per share data)

(unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020		2022		2021		2022		2021
Operating expenses:
Research and development	$	3,233	$	1,892	$	5,212	$	4,007	$	5,717	$	3,233	$	13,795	$	5,212
General and administrative		2,507		823		4,425		1,363		3,209		2,507		6,785		4,425
Total operating expenses		5,740		2,715		9,637		5,370		8,926		5,740		20,580		9,637
Loss from operations		(5,740)		(2,715)		(9,637)		(5,370)		(8,926)		(5,740)		(20,580)		(9,637)
Other income		500		—		500		—		—		500		—		500
Interest income (expense), net		(1)		5		(2)		(17)		2		(1)		3		(2)
Net loss	$	(5,241)	$	(2,710)	$	(9,139)	$	(5,387)	$	(8,924)	$	(5,241)	$	(20,577)	$	(9,139)
Per share information:
Net loss per share of common stock, basic and diluted	$	(0.46)	$	(2.45)	$	(0.83)	$	(4.89)	$	(0.74)	$	(0.46)	$	(1.70)	$	(0.83)
Weighted-average common shares outstanding, basic and diluted		11,456,991		1,104,327		11,051,185		1,101,798		12,127,385		11,456,991		12,125,156		11,051,185

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Statements of Changes in ~~Convertible Preferred Stock and~~ Stockholders’ Equity ~~(Deficit~~)

(In thousands, except share data)

(unaudited)

Convertible preferred stock

Stockholders’ equity

Series A

Common stock

Additional





paid-in

Accumulated


Shares

Amount

Shares

Amount

capital

deficit

Total
Balance at March 31, 2021

—

$
—

10,660,181

$
1

$
96,174

$
(58,292)

$
37,883
Sale of common stock and common stock warrants, net of $596 in offering costs

—

—

1,000,000

—

26,404

—

26,404
Share-based compensation expense

—

—

—

—

749

—

749
Exercise of common stock warrants

—

—

134,351

—

801

—

801
Exercise of stock options

—

—

18,260

—

21

—

21
Net loss

—

—

—

—

—

(5,241)

(5,241)
Balance at June 30, 2021

—

$
—

11,812,792

$
1

$
124,149

$
(63,533)

$
60,617

Convertible preferred stock

Stockholders’ equity

Series A

Common stock

Additional





paid-in

Accumulated


Shares

Amount

Shares

Amount

capital

deficit

Total
Balance at January 1, 2021

10,634,245

$
1

$
95,738

$
(54,394)

$
41,345
Sale of common stock and common stock warrants, net of $596 in offering costs

—

$
—

1,000,000

—

26,404

—

26,404
Share-based compensation expense

—

—

—

—

1,074

—

1,074
Exercise of common stock warrants

—

—

146,017

—

906

—

906
Exercise of stock options

—

—

32,530

—

27

—

27
Net loss

—

—

—

—

—

(9,139)

(9,139)
Balance at June 30, 2021

—

$
—

11,812,792

$
1

$
124,149

$
(63,533)

$
60,617


	Convertible preferred stock			Stockholders’ deficit									Stockholders’ equity
	Series A			Common stock			Additional						Common stock			Additional
							paid-in		Accumulated							paid-in		Accumulated
	Shares	Amount		Shares	Amount		capital		deficit		Total		Shares	Amount		capital		deficit		Total
Balance at March 31, 2020	4,447,981	$	38,939	1,099,270	$	—	$	1,073	$	(39,234)	$	(38,161)
Sale of Series A convertible preferred stock	1,222,203		9,452	—		—		—		—		—
Balance at March 31, 2022													12,127,385	$	1	$	128,631	$	(90,758)	$	37,874
Share-based compensation expense	—		—	—		—		39		—		39	—		—		1,327		—		1,327
Exercise of stock options	—		—	13,123		—		3		—		3
Net loss	—		—	—		—		—		(2,710)		(2,710)	—		—		—		(8,924)		(8,924)
Balance at June 30, 2020	5,670,184	$	48,391	1,112,393	$	—	$	1,115	$	(41,944)	$	(40,829)
Balance at June 30, 2022													12,127,385	$	1	$	129,958	$	(99,682)	$	30,277

	Convertible preferred stock			Stockholders’ deficit									Stockholders’ equity
	Series A			Common stock			Additional						Common stock			Additional
							paid-in		Accumulated							paid-in		Accumulated
	Shares	Amount		Shares	Amount		capital		deficit		Total		Shares	Amount		capital		deficit		Total
Balance at January 1, 2020	4,443,259	$	38,894	1,099,270	$	—	$	927	$	(36,557)	$	(35,630)
Sale of Series A convertible preferred stock	1,226,925		9,497	—		—		—		—		—
Balance at January 1, 2022													12,110,373	$	1	$	127,289	$	(79,105)	$	48,185
Share-based compensation expense	—		—	—		—		185		—		185	—		—		2,637		—		2,637
Exercise of stock options	—		—	13,123		—		3		—		3	17,012		—		32		—		32
Net loss	—		—	—		—		—		(5,387)		(5,387)	—		—		—		(20,577)		(20,577)
Balance at June 30, 2020	5,670,184	$	48,391	1,112,393	$	—	$	1,115	$	(41,944)	$	(40,829)
Balance at June 30, 2022													12,127,385	$	1	$	129,958	$	(99,682)	$	30,277

													Stockholders’ equity
													Common stock			Additional
																paid-in		Accumulated
													Shares	Amount		capital		deficit		Total
Balance at March 31, 2021													10,660,181	$	1	$	96,174	$	(58,292)	$	37,883
Sale of common stock and common stock warrants, net of $596 in offering costs													1,000,000		—		26,404		—		26,404
Share-based compensation expense													—		—		749		—		749
Exercise of common stock warrants													134,351		—		801		—		801
Exercise of stock options													18,260		—		21		—		21
Net loss													—		—		—		(5,241)		(5,241)
Balance at June 30, 2021													11,812,792	$	1	$	124,149	$	(63,533)	$	60,617

													Stockholders’ equity
													Common stock			Additional
																paid-in		Accumulated
													Shares	Amount		capital		deficit		Total
Balance at January 1, 2021													10,634,245	$	1	$	95,738	$	(54,394)	$	41,345
Sale of common stock and common stock warrants, net of $596 in offering costs													1,000,000		—		26,404		—		26,404
Share-based compensation expense													—		—		1,074		—		1,074
Exercise of common stock warrants													146,017		—		906		—		906
Exercise of stock options													32,530		—		27		—		27
Net loss													—		—		—		(9,139)		(9,139)
Balance at June 30, 2021													11,812,792	$	1	$	124,149	$	(63,533)	$	60,617

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

IMMUNOME, INC.

Condensed Statements of Cash Flows

(In thousands)

(unaudited)


	Six Months Ended June 30,				Six Months ended June 30,
	2021		2020		2022		2021
Cash flows from operating activities:
Net loss	$	(9,139)	$	(5,387)	$	(20,577)	$	(9,139)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		351		322		224		351
Amortization of right-of-use asset						33		—
Share-based compensation		1,074		185		2,637		1,074
Deferred rent		(3)		—		(12)		(3)
Forgiveness of PPP Loan		(500)		—		—		(500)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		142		186		4,460		142
Accounts payable		486		874		2,182		486
Accrued expenses and other current liabilities		313		276		(3,342)		313
Other long-term liabilities						(41)		-
Net cash used in operating activities		(7,276)		(3,544)		(14,436)		(7,276)
Cash flows from investing activities:
Purchases of property and equipment		(39)		(416)		(176)		(39)
Net cash used in investing activities		(39)		(416)		(176)		(39)
Cash flows from financing activities:
Proceeds from sale of Series A convertible preferred stock		—		11,046
Payment of Series A convertible preferred stock issuance costs		—		(27)
Proceeds from sale of common stock and common stock warrants		27,000		—		—		27,000
Payment of issuance costs related to the sale of common stock and common stock warrants		(486)		—
Payment from issuance costs related to the sale of common stock and common stock warrants						—		(486)
Proceeds from exercise of stock options		27		3		32		27
Proceeds from exercise of stock warrants		906		—
Proceeds from long-term debt		—		500
Proceeds from exercise of common stock warrants						—		906
Payment of equipment loan payable		(69)		(112)		—		(69)
Payment of capital lease obligations		—		(204)
Net cash provided by financing activities		27,378		11,206		32		27,378
Net increase in cash and restricted cash		20,063		7,246
Cash and restricted cash at beginning of period		39,866		2,643
Cash and restricted cash at end of period	$	59,929	$	9,889
Net increase (decrease) in cash and cash equivalents and restricted cash						(14,580)		20,063
Cash and cash equivalents and restricted cash at beginning of period						49,329		39,866
Cash and cash equivalents and restricted cash at end of period					$	34,749	$	59,929

Supplemental disclosures of cash flow information:
Cash paid for interest	$	—	$	17
Supplemental disclosures of non-cash investing and financing activities:
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock	$	—	$	1,522
Purchases of property and equipment in accounts payable	$	7	$	—
Offering costs in accounts payable	$	110	$	—
Operating lease right-of-use asset and lease liability recorded upon adoption of ASC 842					$	215	$	—
Offering costs included in accounts payable					$	—	$	110
Purchases of property plant and equipment included in accounts payable					$	—	$	7

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

IMMUNOME, INC.

Notes to Condensed Financial Statements

(Unaudited)

1. Nature of the business and basis of presentation

Organization

Immunome, Inc. ~~(the Company~~(“the Company” or ~~Immunome)~~“Immunome”) was incorporated as a Pennsylvania corporation on March 2, 2006 and was converted to a Delaware corporation on December 2, 2015. The Company is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The Company’s primary focus areas are oncology and infectious disease, including COVID-19.

Since its inception, the Company has devoted substantially all its resources to research and development, raising capital, building its management team and ~~building~~extending its intellectual property portfolio. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited ~~to; technical~~to, risks associated with the successful research, development and manufacturing of product candidates, uncertain results of preclinical and clinical testing, development ~~by competitors~~ of new technological innovations and products by competitors, dependence on key personnel and third-party vendors, protection of proprietary technology, compliance with government regulations, ~~and~~ regulatory approval of product candidates and the ability to secure additional capital to fund operations.

Liquidity

The Company has incurred net losses since inception, including net losses ~~$9.1~~of $20.6 million and ~~$5.4~~$9.1 million for the six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, and it expects to generate losses from operations and negative operating cash flows for the foreseeable future primarily due to research and development costs for its potential product candidates. As of June 30, ~~2021,~~2022, the Company had an accumulated deficit of ~~$63.5~~$99.7 million. ~~The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.~~

On ~~April 28,~~October 1, 2021 the Company ~~sold 1,000,000 units, consisting of 1 share of~~entered into an Open Market Sale Agreement (“ATM Agreement”) with Jefferies Group LLC, which provides that, upon the ~~Company’s common stock~~terms and ~~1 warrant~~subject to ~~purchase one-half a share~~the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of common stock ~~in a private placement at a price of $27.00 per unit for net proceeds of $26.4 million. On October 6, 2020,~~under the ~~Company closed its initial public offering (IPO), in which the Company issued and sold 3,250,000 shares of its common stock at a public~~registration statement having an aggregate offering price of ~~$12.00 per share. On October 13, 2020, the underwriters exercised their option~~up to ~~purchase an additional 487,500 shares of the Company’s common stock at a purchase price of $12.00 per share.~~$75.0 million through Jefferies Group LLC acting as sales agent. The Company ~~received net proceeds of $41.7 million after deducting underwriting discounts and commissions of $3.1 million but before deducting other offering expenses.~~has not yet sold any shares under the ATM Agreement.

The Company had cash and cash equivalents of ~~$59.8~~$34.6 million at June 30, ~~2021.~~2022. The Company expects that its cash will enable it to fund its operating expenses and capital expenditure requirements for at least ~~twelve~~12 months from the filing date of this Quarterly Report on Form ~~10-Q. However, additional~~10-Q; however; more funding will be necessary beyond this point to fund additional research and development, clinical development and operations in order to pursue ~~its~~the Company’s growth strategy.

If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize ~~independently;~~independently (or enter into these collaborations sooner than it might otherwise have intended to do); consider other various strategic alternatives, including a merger or sale of the Company; or reduce or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products or technologies than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the ~~product~~research and development process. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds.

~~Table of Contents~~

Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant

Table of Contents

their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. On March 11, 2020, the World Health Organization characterized the novel ~~COVID 19~~COVID-19 virus as a global pandemic. Although there is significant uncertainty as to the likely effects this disease may have in the future, ~~to date~~ there has not been a significant impact to the Company’s operations or financial ~~results.~~

statements to date.

2. Summary of significant accounting policies

Basis of presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted ~~(GAAP)~~(“GAAP”) in the United States. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ~~(ASC)~~(“ASC”) and Accounting Standards Updates ~~(ASU)~~(“ASU”) promulgated by the Financial Accounting Standards Board ~~(FASB)~~(“FASB”).

Unaudited interim results

These unaudited condensed financial statements and accompanying notes should be read in conjunction with the Company’s annual financial statements and the notes thereto included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March ~~25, 2021.~~28, 2022. The accompanying condensed financial statements as of June 30, ~~2021~~2022 and for the three and six months ended June 30, ~~2021~~2022 and ~~2020~~2021 are unaudited but include all adjustments that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, ~~2020~~2021 have been derived from the audited financial statements as of that date.

~~Reverse stock split~~

~~The Company’s board of directors approved a one-for-six~~ reverse stock split of its issued and outstanding common stock, stock options, convertible preferred stock and convertible preferred stock warrants legally effective as of September 22, 2020. Accordingly, all convertible preferred shares and common shares, common stock warrants, per share amounts, and additional paid-in capital amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options and accrued research and development expenses. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the ~~Company’s common stock~~period in ~~connection with share-based compensation arrangements.~~which they become known. Actual results could differ from these estimates.

Segment and geographic information

Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company’s Chief Executive Officer. The Company views its operations as and manages its business in 1 operating segment operating exclusively in the United States.

Fair value of financial instruments

ASC Topic 820, Fair Value Measurement ~~(ASC 820)~~(“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market

Table of Contents

~~the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market~~ participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:

Level 1 — Quoted market prices in active markets for identical assets or liabilities.

Level 2 — Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3 — Unobservable inputs for the asset or liability (i.e.; supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).

To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair ~~values~~value requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Cash and cash equivalents are Level 1 assets as of June 30, 2022 and December 31, 2021.

Restricted cash

Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company’s lease of its corporate facilities. This lease expires in ~~2022~~2024 at which time the cash will be released from restriction. Restricted cash was $100,000 at both June 30, 2022 and 2021, ~~and 2020.~~respectively. The following table provides a reconciliation of the components of cash and cash equivalents and restricted cash reported in the Company’s condensed ~~consolidated~~ balance sheets to the total of the amount presented in the condensed ~~consolidated~~ statements of cash flows:


(in thousands)	June 30, 2021		June 30, 2020		June 30, 2022		June 30, 2021
Cash	$	59,829	$	9,789
Cash and cash equivalents					$	34,649	$	59,829
Restricted cash		100		100		100		100
	$	59,929	$	9,889	$	34,749	$	59,929

Equity issuance costs

The Company ~~capitalized incremental legal, professional, accounting and other third-party fees~~capitalizes costs that ~~were~~are directly associated with the ~~April 2021 equity~~ATM Agreement until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred offering ~~and~~costs are expensed. Ongoing costs that are directly associated with the ~~IPO~~ATM Agreement are expensed as ~~other noncurrent assets until the~~incurred.

Deferred offering ~~and IPO each were consummated. After consummation of the offering and IPO, these~~ costs were ~~recorded in stockholders’ equity~~$0.3 million and $0.3 million as ~~a reduction of additional paid-in-capital generated as a result of the offering and IPO. As~~ of June 30, ~~2021~~2022 and December 31, ~~2020, there were 0 deferred offering costs.~~2021, respectively, on the condensed balance sheet.

Government ~~contract funding~~assistance programs

The Company accounts for amounts received under its U.S. Department of Defense (“DoD”) expense reimbursement contract as contra-research and development expenses in the condensed statements of operations. The Company accounts for the employee retention credit received under the U.S. Department of Treasury Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) as contra-expense to personnel related costs within research and development and general and administrative expenses in the condensed statements of operations.

Research and development costs

Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, share-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, preclinical expenses, consulting and other contracted services. Additionally, under the terms of the license agreements, the Company is obligated to make future payments should certain development and regulatory milestones be achieved. NaN such costs have been incurred for the three and six months ended June 30, 2021 and 2020. Costs for certain research and

Table of Contents

compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, preclinical and clinical development expenses, including manufacture and testing of clinical supplies, consulting and other contracted services. Additionally, under the terms of the license agreements described in Note 7, the Company is obligated to make future payments should certain development and regulatory milestones be achieved. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the ~~pattern~~timing of ~~costs incurred,~~receipt of invoices and payment of invoices and are reflected in the financial statements as a prepaid or accrued expense.

Net loss per share

The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

Basic net loss per share of common stock is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share of common stock is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share of common stock is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.

The following potentially dilutive securities outstanding as of June 30, ~~2021~~2022 and ~~2020~~2021 have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:


	June 30,		June 30,
	2021	2020	2022	2021
Stock options⁽¹⁾	2,016,036	1,003,516	2,532,644	2,016,036
Common stock warrants⁽¹⁾	1,362,181	—	1,303,112	1,362,181
Convertible preferred stock⁽¹⁾	—	5,670,295
	3,378,217	6,673,811	3,835,756	3,378,217

(1)	Represents common stock equivalents.

Prior to its conversion, the Company’s Series A convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to participating securities. In periods in which the Company reports a net loss per share of common stock, diluted net loss per share of common stock is the same as basic net loss per share of common stock since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss per share of common stock for the three and six months ended June 30, ~~2021~~2022 and ~~2020.~~2021.

~~Segment~~Leases

Effective January 1, 2022, the Company adopted ASU No. 2016-02, Leases (“ASC 842”) using the modified retrospective approach by applying the new standard to all leases existing on the adoption date. The results for reporting periods beginning after January 1, 2022 are presented in accordance with ASC 842, while prior period amounts are not adjusted and ~~geographic information~~continue to be reported under the accounting standards that were in effect prior to January 1, 2022.

At the inception of an arrangement, the Company determines whether an arrangement contains a lease based on facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Typically, lessees are required to recognize leases with a term greater than one year on the balance sheet as an operating or finance lease liability and right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The Company has elected the practical expedient to not to recognize leases with a term of 12 months or less. The Company does not have any financing leases as of June 30, 2022.

Operating ~~segments~~lease liabilities and their corresponding right-of-use assets are ~~defined as components~~recorded based on their present value of ~~an entity about which separate discrete information is available for evaluation by~~lease payments over the ~~chief operating decision maker (CODM), or decision-making group,~~remaining lease term. Options to extend the lease term are included in ~~deciding how to allocate resources and in assessing performance. The CODM is~~ the Company’s ~~Chief Executive Officer. The~~assessment of the lease term only if there is a reasonable assessment that the Company ~~views~~will renew. Leases are discounted to its ~~operations as and manages its business in 1 operating segment operating exclusively~~present value using either the interest rate implicit in the ~~United States.~~Company’s lease or its incremental borrowing rate, which

Table of Contents

reflects the fixed rate in which the Company could borrow on a collateralized basis the amount of lease payments in the same currency, for a similar term, in a similar economic environment.

Recently adopted accounting standards

On January 1, 2022, the Company adopted ASC 842, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840. The standard generally requires lessees to recognize operating and finance lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and provide enhanced disclosures on the amount, timing, and uncertainty of cash flows arising from lease arrangements. The Company adopted ASC 842 using the modified retrospective approach. The Company elected the package of practical expedients available for existing contracts, which allowed the Company to carry forward our historical assessments of lease identification, lease classification, and initial direct costs. The Company also elected a policy to not apply the recognition requirements of ASC 842 for short-term leases with a term of 12 months of less.

As of January 1, 2022, the effective date, the Company identified one operating lease arrangement relating to the Company’s headquarters facility and one short-term lease relating to laboratory equipment. The adoption of ASC 842 resulted in a recognition of an ROU asset and lease liability of $0.2 million on the Company’s balance sheet relating to the leases as of January 1, 2022. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations and condensed statements of cash flows (Note 8).

Recently issued accounting pronouncements

In November 2021, the FASB issued ASU Topic 832, Disclosures by Business Entities about Government Assistance (“ASC 832”). This standard requires annual disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about the types of transactions, the accounting for the transactions, and the effect of the transactions on an entity’s financial statements. The effective date of ASC 832 is for financial statements issued for annual periods beginning after December 15, 2021. The Company is currently evaluating the effect ASC 832 will have on its financial statements and related disclosures.

3. ~~U.S. Department of Defense (DoD)~~Government assistance programs

DoD expense reimbursement contract

In July 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the ~~OTA Agreement)~~“OTA Agreement”) with the DoD to fund the Company’s efforts in developing ~~Biosynthetic Convalescent Plasma (BCP)~~an antibody cocktail therapeutic to treat COVID-19. Under the OTA Agreement, the Company intends to develop BCP for use in the U.S. military population and the U.S. population as a whole, subject to approval by the U.S. Food and Drug Administration (FDA). The amount of funding ~~being~~originally made available to the Company under this expense reimbursement contract was $13.3 million. In May

~~Table of Contents~~

2021, the Company and the DoD amended the OTA Agreement, pursuant to which the DoD award was increased from $13.3 million to $17.6 million. ~~Based on~~Under the ~~Company’s currently anticipated expenditures,~~OTA Agreement, the ~~$17.6 million~~DoD is ~~expected~~required to ~~be received through 2021.~~

pay the Company, upon submission of proper invoices, within 30 calendar days of receipt of request for payment.

The Company recorded contra-research and development expense related to the OTA Agreement of $0.01 million and $0.6 million for the three and six months ended June 30, 2022, respectively, in the ~~amount~~condensed statements of operations. The Company recorded contra-research and development expense related to the OTA Agreement of $4.1 million and $8.1 million for the three and six months ended June 30, 2021, respectively, in the condensed statements of operations. ~~There was 0 contra-research and development expense for the three and six months ended June 30, 2020. As of June 30, 2021, the~~The Company had an expense reimbursement receivable balance of ~~$1.7~~$0.2 million and $2.7 million due from the DoD in prepaid expenses and other current assets onas of June 30, 2022 and December 31, 2021, respectively, in the accompanying condensed balance ~~sheet.~~ sheets.

Costs that have been reimbursed by the DoD but not yet expensed by the Company are recorded as a deferred research obligation liability for the period. ~~As of June 30, 2021, the~~The Company has a deferred research obligation liability of ~~$0.5 million.~~$0.01 million and $2.0 million as of June 30, 2022 and December 31, 2021, respectively. This amount is included in accrued expenses and other liabilities in the accompanying condensed balance sheets. DoD reimbursable services that have been performed but not yet billed are recorded as an unbilled receivable in prepaid expenses and other current assets in the accompanying

Table of Contents

condensed balance sheets. The Company had an unbilled receivable from the DoD of $0 and $1.6 million as of June 30, 2022 and December 31, 2021, respectively.

As of June 30, 2022, the Company has received $17.4 million in expense reimbursement from the DoD under the OTA Agreement.

U.S. Department of Treasury CARES Act employee retention credit

Under the CARES Act, the Company met eligibility criteria for a $0.8 million refundable employee retention credit. The Company recorded contra-expense to personnel related costs within research and development expense of $0.6 million and contra-general administrative expense of $0.2 million for the three and six months ended June 30, 2022, respectively, in the condensed statements of operations. NaN such amounts were recognized for the three and six months ended June 30, 2021. The Company had an employee retention credit receivable balance due from the U.S. Department of Treasury of $0.8 million and $0 in prepaid expenses and other current assets as of June 30, 2022 and December 31, 2021, respectively, in the accompanying condensed balance sheets.

4. Prepaid expenses and other assets

Prepaid expenses and other assets consisted of the following:


(in thousands)	June 30, 2022		December 31, 2021
CARES Act employee retention credit receivable	$	847	$	—
Prepaid insurance		830		2,019
Research and development advance payments		501		586
Other prepaids and short-term deposits		528		492
Reimbursement receivable from DoD		243		2,674
Unbilled reimbursement receivable from DoD		—		1,638
	$	2,949	$	7,409

4.5. Accrued expenses and other liabilities

Accrued expenses and other liabilities consisted of the following:

(in thousands)

June 30, 2021

December 31, 2020

Deferred research obligations

486

—

Compensation and related benefits

653

845

Professional fees, contractors and other

548

527

$
1,687

$
1,372


(in thousands)	June 30, 2022		December 31, 2021
Research and development	$	2,205	$	2,840
Compensation and related benefits		932		1,246
Professional fees		134		227
Short-term operating lease liability and other liabilities		66		317
Deferred research obligations		22		2,021
	$	3,359	$	6,651

6. Long-term debt

On April 30, 2020, the Company entered into a loan agreement with Silicon Valley Bank as the lender ~~(Lender)~~(“Lender”) for a loan in an aggregate principal amount of $0.5 million ~~(the~~ (“PPP ~~Loan)~~Loan”) pursuant to the Paycheck Protection Program ~~(PPP)~~(“PPP”) under the ~~Coronavirus Aid, Relief, and Economic Security (CARES)~~CARES Act and implemented by the U.S. Small Business Administration ~~(SBA)~~(“SBA”). The Company used the proceeds of the PPP Loan for payroll and other qualifying expenses. The entire PPP Loan was forgiven on May 21, 2021 and recognized as other income in the ~~statement~~condensed statements of operations.

~~6. Commitments and contingencies~~

~~Operating leases~~

In May 2017, the Company entered into a 62 month office and laboratory space lease commencing on July 1, 2017 for approximately 11,000 square feet of space in Exton, Pennsylvania. The Company has an option to extend the lease for 2 additional five-year terms. The lease is subject to fixed rate escalation increases and the landlord waived the Company’s rent obligation for the first two months of the lease. Deferred rent is $13,000 and $16,000 as of June 30, 2021 and December 31, 2020, respectively, and is being amortized as a reduction in rent expense over the term of the lease. The Company recognizes rent expense on a straight-line basis over the expected lease term.

~~In August 2020, the Company entered into a one-year operating lease for laboratory equipment that expired in July 2021 and had fixed monthly payments of $18,000~~.

1112

Table of Contents

~~Future minimum lease payments for the Company’s operating leases are as follows as of June 30, 2021 (in thousands):~~

Years ending December 31,

Amount
2021 (represents remaining six months in 2021)

$
132
2022

153

$
285

~~Rent expense was $0.1 million for each of the three months ended June 30, 2021~~7. Commitments and ~~2020, respectively, and $0.1 million and $0.2 million for the six months ended June 30, 2021 and 2020, respectively.~~contingencies

Employment agreements

The Company entered into employment ~~offer letter~~ agreements (the ~~Employment Agreements)~~“Employment Agreements”) with certain key personnel providing for compensation and severance in certain circumstances, as defined in the respective Employment Agreements. The Employment Agreements may be terminated by either the Company or the employees in accordance with the respective Employment Agreements (subject to the payment of severance upon certain terminations) and provide for annual pay ~~increases~~adjustments and bonuses at the discretion of the Board of Directors.

Employee benefit plan

The Company maintains a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the ~~401(k) Plan)~~“401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company assumes all administrative costs of the 401(k) Plan and makes matching contributions as defined in the 401(k) Plan document. The Company made matching contributions of ~~$30,000 and $16,000~~$0.1 million to the 401(k) Plan for each of the three ~~months ended June 30, 2021~~ and ~~2020, respectively, and $69,000 and $32,000 for the~~ six months ended June 30, 2022 and 2021, ~~and 2020,~~ respectively.

Legal proceedings

The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies.

~~Patent~~ License ~~Agreement~~Agreements

~~In June 2021, the~~The Company entered into ~~an exclusive worldwide patent~~various license ~~agreement with several Philadelphia based universities and hospitals (“the Licensors”)~~agreements to further discover, develop and commercialize ~~human antibodies, identified using Immunome’s human hybridoma technology, for the treatment of diseases associated with the formation of bacterial biofilms.~~certain technologies and treatments. The ~~Licensors are eligible~~Company may need to ~~receive up to $0.4 million in~~pay developmental ~~milestone payments, up to $1.5 million in~~and regulatory milestone payments ~~and~~of up to ~~$0.8 million commercial milestone payments.~~approximately $2.6 million. In addition, the ~~Licensors are eligible~~Company may need to ~~receive low single digit~~pay royalty rates ~~for~~on net product sales ~~which are subject~~and certain commercial milestone payments of up to ~~adjustment~~approximately $1.5 million, if any.

The Company recorded $0.1 million milestone payments during the three and six months ended June 30, 2022, respectively, in research and development expenses in the ~~event~~condensed statements of operations. NaN such costs were recorded during the ~~Company sublicenses the approved technology. Beginning in~~three and six months ended June 30, 2021, respectively.

8. Leases

Effective January 1, 2022, the Company ~~is subject~~adopted ASC 842 using the modified retrospective approach by applying the new standard to ~~annual minimum payments~~all leases existing on the adoption date. The results for reporting periods beginning after January 1, 2022 are presented in accordance with ASC 842, while prior period amounts are not adjusted and continue to be reported under the ~~Licensors~~accounting standards that were in effect prior to January 1, 2022. The Company elected the practical expedient to recognize short-term leases under ASC 840.

In May 2017, the Company entered into a 62-month office and laboratory space lease commencing on July 1, 2017 for approximately 11,000 square feet of ~~$20,000, which increases~~space in Exton, Pennsylvania. The Company has an option to ~~$30,000 annually~~extend the lease for up to 2 additional five-year terms. In December 2021, the Company extended the lease for an additional eighteen-month term ending in ~~June 2023 and thereafter.~~March 2024.

Beginning July 2021, the Company leased laboratory equipment on a month-to-month basis. In April 2022, the Company terminated the agreement through exercising the option to purchase the leased laboratory equipment under the lease agreement.

1213

Table of Contents

~~7. Common stock~~Supplemental balance sheet information related to leases as of June 30, 2022 was as follows (in thousands):


Operating leases:
Operating lease right-of-use assets	$	182

Operating lease liability	$	64
Operating lease liability, net of current portion		124
Total operating lease liability	$	188

Operating lease liability and ~~convertible preferred~~operating lease liability, net of current portion is included in accrued expenses and other current liabilities and other long-term liabilities, respectively, in the accompanying condensed balance sheets.

Supplemental lease expense related to leases was as follows:


Lease Cost (in thousands)	Statements of Operations Classification		Three Months Ended June 30, 2022	Six Months Ended June 30, 2022
Operating lease cost	General and administrative Research and development	$	60	121
Short-term lease cost	General and administrative Research and development		-	53
Total lease expense		$	60	174

Under ASC 840, rent expense was $0.1 million for each of the three and six months ended June 30, 2021, respectively.

Other information related to the operating lease where the Company is the lessee was as follows:


		Six Months Ended June 30, 2022
Weighted-average remaining lease term (in years)		1.75
Weighted-average discount rate		9.0%

Supplemental cash flow information related to the operating lease was as follows (in thousands):


		Six Months Ended June 30, 2022
Cash paid for operating lease liability	$	114

As of June 30, 2022, minimum rental commitments under the operating lease were as follows (in thousands):


Years ending December 31,	Amount
2022 (represents remaining six months in 2022)	$	120
2023		246
2024		63
Total lease payments		429
Less imputed interest		(241)
Present value of lease liability	$	188

Table of Contents

9. Common stock

Common stock

The holders of common stock are entitled to 1 vote for each share of common stock. Subject to the approval of the holders of a majority in interest of ~~shareholders,~~the Company’s stockholders entitled to vote thereon, the holders of common stock shall be entitled to receive dividends out of ~~funds~~ legally ~~available.~~available funds. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of common stock ~~shall be~~are entitled to share ratably in the remaining assets of the Company available for distribution.

On April 28, 2021, the Company sold 1,000,000 units, each unit comprising 1 share of the Company’s common stock and 1 Series B Warrant (each, a ~~Series~~“Series B ~~Warrant)~~Warrant”) to purchase one-half of a share of common stock. The units were issued in a private placement at a price of $27.00 per unit for gross proceeds of $27.0 million. The Series B Warrants are equity-classified, exercisable at any time, have an exercise price of ~~$45.00~~$45.00 per share and will terminate at three years from the date of issuance. The fair value of the warrants on the date of issuance was $6.0 million. The fair value of the warrants was estimated using a Black-Scholes Option Pricing Model. The significant assumptions used in preparing the option pricing model for valuing the Company's warrants to purchase shares of common stock as of April 28, 2021 included (i) volatility of 82.7%, (ii) risk free interest rate of 0.35%, (iii) strike price of $45.00 erper share, (iv) fair value of common stock of $28.70 per share, and (v) expected life of 3three years. The Series B Warrants are callable by the Company in certain circumstances.

~~On October 6, 2020, the Company closed the IPO in which the Company issued and sold~~ ~~3,737,500 shares of its common stock at a public offering price of $12.00 per share, including 487,500~~ ~~shares of the Company’s common stock sold pursuant to the underwriters’ option to purchase additional shares. The Company received net proceeds of~~ $41.7 million after deducting underwriting discounts and commissions of $3.1 million but before deducting other offering expenses. The Company’s common stock is listed on the Nasdaq Capital Market under the trading symbol “IMNM.” On October 6, 2020, the Company filed an amended and restated certificate of incorporation to, among other things, increase the number of shares of common stock, $0.0001 par value per share, authorized for issuance to 200,000,000 and authorize the Company’s board of directors to issue up to 10,000,000 shares of “blank check” preferred stock, $0.0001 par value per share.

~~Series A convertible preferred stock~~

Prior to the IPO, all of the Company’s convertible preferred stock was classified outside of stockholders’ deficit because the shares contained certain redemption features that were not solely within the control of the Company. At the time of issuance, the redeemable convertible preferred stock was recorded at its issuance price, less issuance costs.

During the year ended December 31, 2019, the Company sold 512,826 shares of its Series A Preferred at $9.00 per share in exchange for $4.6 million in gross proceeds and incurred $35,000 of related issuance costs and issued 821,657 shares of Series A Preferred in connection with the conversion of the promissory notes of $6.8 million. In 2020, the Company completed the sale of an additional 1,226,925 shares of Series A Preferred at $9.00 per share, resulting in gross cash proceeds of $11.0 million, which includes 4,722 shares issued in January 2020 for gross receipts of $45,000. During the six months ended June 30, 2020, the Company sold 1,226,925 shares of Series A Preferred for net proceeds of $9.5 million and issued 1,035,196 warrants to purchase shares of the Company’s Series A Preferred with a fair value of $1.5 million. The warrants were exercisable at any time and had an exercise price of $9.00 per share and were to terminate at the earlier of (i) three years from the date of issuance, (ii) upon liquidation of the Company and (iii) upon the Company’s securities trading at $27.00 per unit for at least 10 days out of a consecutive 20-day trading period beginning after the first anniversary of the IPO. The warrants were originally liability-classified as the underlying Series A convertible preferred stock was contingently redeemable and outside of the Company’s control. Upon completion of the IPO on October 6, 2020, the warrants became exercisable for shares of the Company’s common stock and the $7.1 million warrant liability was reclassified to additional paid-in capital.

In connection with the Company’s sale of its Series A Preferred in 2015, a future milestone closing provision (the Future Milestone) was included requiring the Company to sell, on the same terms and conditions as the initial offering,

~~Table of Contents~~

an aggregate of $3.5 million of additional Series A Preferred upon achievement of certain development and strategic milestones, as defined in the purchase agreement and at $9.00 per share, or 388,888 shares of Series A Preferred. The Future Milestone did not occur and the Company’s obligations under this right terminated upon completion of the Company’s IPO.

The Company determined that the future tranche right related to the Future Milestone did not meet the definition of a freestanding financial instrument as it was not legally detachable. The future tranche right was also evaluated as an embedded derivative and the Company determined it did not meet the definition of a derivative instrument for which bifurcation would be required.

In connection with the IPO, all of the Series A Preferred converted into 5,670,184 shares of common stock and all of the outstanding warrants to purchase convertible preferred stock converted into warrants to purchase common stock.

Warrants to acquire shares of common stock

At June 30, ~~2021~~2022, common stock warrants outstanding were as follows:


Warrants	Exercise Price per Share	Expiration Date	Exercise Price per Share	Expiration Date
862,181	$ 9.00	June 2, 2023
803,112			$ 9.00	June 2, 2023
500,000	$ 45.00	April 28, 2024	$ 45.00	April 28, 2024

During the six months ended June 30, 2022, 0 warrants were exercised. During the six months ended June 30, 2021, 100,695 warrants were exercised, and the Company received proceeds of $0.9 million and 100,695 shares of the Company’s common stock were issued. Additionally, 72,320 warrants were cashless exercised during the six months ended June 30, 2021 and 45,322 shares of the Company’s common stock were issued.

8.10. Share-based compensation

In July 2008, the ~~board~~Board of ~~directors~~Directors adopted the 2008 Equity Incentive Plan (the ~~2008 Plan)~~“2008 Plan”) which provided for the grant of qualified incentive stock options and ~~nonqualified~~non-qualified stock options, restricted stock or other awards to the Company’s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company’s common stock. The 2008 Plan was replaced in July 2018 with the ~~Immunome, Inc.~~ 2018 Equity Incentive Plan ~~(the 2018~~(2018 Plan and collectively with the 2008 Plan, the ~~Plans)~~“Prior Plans”). At the time that the 2008 Plan was terminated, there were 388,748 shares available for grant that were transferred to the 2018 Plan. ~~Any additional shares that become available for grant under the 2008 Plan are automatically transferred to and made available for grant under the 2018 Plan.~~ On September 24, 2020, the 2018 Plan was terminated and replaced with the 2020 Equity Incentive Plan (the ~~2020 Plan)~~“2020 Plan”). Additionally, the number of shares of our common stock reserved for issuance under ~~our~~the 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021 and continuing through and including January 1, 2030, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by ~~our board~~the Company’s Board of ~~directors.~~Directors. As of June 30, ~~2021,~~2022, there were ~~1,591,121~~1,313,412 shares available for future issuance under the 2020 Plan.

The Company also adopted the 2020 Employee Stock Purchase Plan ~~(the ESPP Plan)~~(“ESPP”) on September 18, 2020 which provides for the grant of purchase rights to purchase shares of the Company’s common stock to eligible employees, as defined by the ESPP Plan. The maximum number of shares of common stock that may be issued under the ESPP Plan will not exceed 125,000 shares of common stock, plus the number of shares of common stock that are automatically added on January 1st of each calendar year for a period of up to ten years, commencing on the first January 1st following the year in which an IPO occurs and ending on, and including, January 1, 2030, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, and (ii) 1,000,000 shares of common stock. NaN ~~awards have been granted under the ESPP Plan as of June 30, 2021.~~

1415

Table of Contents

defined by the ESPP. The maximum number of shares of common stock that may be issued under the ESPP will not exceed 125,000 shares of common stock, plus the number of shares of common stock that are automatically added on January 1 of each calendar year for a period of up to ten years, commencing on the first January 1 following the year in which an IPO occurs and ending on, and including, January 1, 2030, in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 1,000,000 shares of common stock. NaN shares of common stock have been issued under the ESPP as of June 30, 2022.

The 2020 Plan and the ESPP ~~Plan~~ are administered by the ~~board~~Board of ~~directors.~~Directors subject to the Board’s right to delegate to a committee. The exercise prices, vesting and other restrictions are determined at the discretion of the ~~board~~Board of ~~directors.~~Directors. Stock options awarded under the Prior Plans and the 2020 Plan generally expire 10 years after the grant date unless the ~~board~~Board of ~~directors~~Directors sets a shorter term. Vesting periods for awards under the Prior Plans and the 2020 Plan are determined at the discretion of the ~~board~~Board of ~~directors. Incentive stock options and non-statutory stock~~Directors. Stock options granted to employees, officers, members of the ~~board~~Board of ~~directors~~Directors and consultants of the Company typically vest over ~~two~~one to four years. Certain options provide for accelerated vesting if there is a change in control, as defined in the Prior Plans and the 2020 Plan.

Share-based compensation expense recorded as research and development and general and administrative expenses in the condensed statements of operations is as ~~follows:~~follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended June 30,				Six Months Ended June 30,
In thousands)	2021		2020		2021		2020
									2022		2021		2022		2021
Research and development	$	368	$	8	$	522	$	55	$	462	$	368	$	907	$	522
General and administrative		381		31		552		130		865		381		1,730		552
	$	749	$	39	$	1,074	$	185	$	1,327	$	749	$	2,637	$	1,074

Unrecognized compensation cost related to unvested options was ~~$12.9~~$12.1 million as of June 30, ~~2021,~~2022 and will be recognized over an estimated weighted average period of ~~3.6~~3.5 years.

Stock options

The weighted average assumptions used in the Black-Scholes option-pricing model for stock options granted were:


	Six Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2022			2021
Expected volatility		83.1	%		80.0	%		85.6	%		83.1	%
Risk-free interest rate		1.1	%		0.8	%		2.7	%		1.1	%
Expected term (in years)		6.04			5.64			5.97			6.04
Expected dividend yield		—			—			—			—
Fair value of common stock	$	25.60		$	1.62		$	3.64		$	25.60

Table of Contents

A summary of option activity under the Plans and 2020 Plan during the six months ended June 30, ~~2021~~2022 is as follows:


				Weighted				Weighted
		Weighted		average		Weighted		average
		average		remaining		average		remaining
	Number of	exercise price		contractual	Number of	exercise price		contractual
	shares	per share		term (years)	shares	per share		term (years)
Outstanding at January 1, 2021	1,472,840	$	3.14	8.51
Outstanding at January 1, 2022					2,005,756	$	11.26	8.50
Granted	581,231	$	25.60		543,900		3.64	9.90
Forfeited	(5,505)	$	8.10		—		—	—
Exercised	(32,530)	$	0.82		(17,012)		1.87	7.86
Outstanding at June 30, 2021	2,016,036	$	9.64	8.54
Exercisable at June 30, 2021	705,784	$	1.13	7.14
Vested or expected to vest at June 30, 2021	2,016,036	$	9.64	8.54
Outstanding at June 30, 2022					2,532,644		9.69	8.41
Exercisable at June 30, 2022					980,061		7.84	7.59
Vested or expected to vest at June 30, 2022					2,532,644		9.69	8.41

The weighted-average grant date fair value per share of stock options granted during the six months ended June 30, 2022 and 2021 was $2.65 and ~~2020 was~~ $18.00, ~~and $1.32,~~ respectively. The aggregate intrinsic value of stock options exercised during the six months ended June 30, ~~2021~~2022 was ~~$0.8~~$0.1 million. The aggregate intrinsic value of stock options outstanding at June 30, ~~2021~~2022 is ~~$20.3~~$1.8 million.

In August 2020, the Company granted stock options exercisable for a total of up to 92,169 shares of common stock to 2 of its officers, which option awards included both performance-based and service-based vesting conditions. These option awards were subsequently modified in September 2020 to eliminate the performance-based criteria. As a result of

~~Table of Contents~~

the modification, only service-based vesting conditions remained. All other terms and conditions of these option awards remain unchanged. Since the performance condition was not considered probable of being achieved prior to the modification, 0 share-based compensation expense was recorded prior to the modification. At the time of the modification, the fair value of these options awards was recalculated at $8.69 per option.

9.11. Related party transactions

License agreements

The Company has entered into license agreements with certain stockholders of the ~~Company, including an additional license agreement in June 2021 with licensors that include one of these stockholders.~~Company. Expenses with these related parties were de minimis for ~~each of~~ the three and six months ended June 30, 2022 and 2021, ~~and 2020,~~ respectively. ~~There were 0~~In addition, amounts owed to these related parties were de minimis as of June 30, ~~2021~~2022 and December 31, ~~2020.~~2021.

Broadband services agreement

In November 2015, the Company entered into a management services agreement ~~(MSA)~~(the “Broadband MSA”) with BCM Advisory Partners LLC and Broadband Capital Partners LLC ~~(Broadband Capital), as subsequently amended and/or restated in July 2016, January 2017, June 2018, March 2020 and August 2020.~~(collectively “Broadband Capital”). Certain directors of the Company are principals of Broadband Capital. Under the Broadband MSA, the Company engages Broadband Capital as a consultant for advice in connection with senior management matters related to the Company’s business, administration and policies in exchange for a cash fee to Broadband Capital of ~~$20,000~~$20,000 per month. The Broadband MSA was amended and/or restated in July 2016, January 2017, June 2018, March 2020 and August 2020. In June 2021, the Company extended the Broadband MSA to continue through June 2022. ~~Pursuant to the Broadband MSA, the Company previously issued an aggregate of~~ ~~827,640 shares of its common stock to Broadband Advisory and has no further obligation to issue additional shares under the Broadband MSA.~~ The Company recorded $0.1 million during each of the three ~~months ended June 30, 2021~~ and ~~2020 and $0.1 million and $0.1 million during the~~ six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, respectively, related to the Broadband MSA, which is included in general and administrative expenses in the condensed statements of operations. Amounts due to Broadband Capital were $0.1 million and $0 as of June 30, 2022 and December 31, 2021, respectively.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form ~~10-Q,~~10-Q, should be read in conjunction with (i) our unaudited interim financial statements and related notes thereto included elsewhere ~~herein.~~herein, (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the United States Securities and Exchange Commission (“SEC”) on March 28, 2022 and (iii) our other public reports filed with the SEC. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts, including express or implied statements regarding ~~our future~~Immunome’s beliefs and expectations regarding the advancement of its platform and programs, execution of its regulatory, research, clinical and strategic plans and anticipated upcoming milestones for its platform and programs, including expectations regarding, among other things, the timing and results of ~~operations~~its preclinical studies and ~~financial position, business strategy, current~~clinical trials, clinical plans, general regulatory actions, the translation of preclinical data into clinical safety and ~~prospective products,~~efficacy, the therapeutic potential and benefits of our product ~~approvals, research~~candidates, the possible need and ~~development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management~~demand for ~~future operations and future results of current and anticipated products,~~its product candidates, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that may cause ~~our~~ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” ”should,”~~should,~~ ”seek,”~~”seek,”“predicts,~~ “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events, ~~and~~ financial trends and other matters that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions ~~described in~~that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones; the fact that research and development data are subject to differing interpretations and assessments; Immunome’s ability to execute on its strategy, including with respect to its R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation, continuation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the effectiveness of Immunome’s product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates and that further variants of concern could emerge; Immunome’s ability to fund operations and raise capital; Immunome’s reliance on vendors; the competitive landscape; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” ~~and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”~~ in ~~our~~Immunome’s Annual Report on Form 10-K filed with the ~~Securities and Exchange~~

~~Table of Contents~~

~~Commission (SEC)~~SEC on March ~~25, 2021~~28, 2022, and ~~other risks described~~elsewhere in ~~our prior~~Immunome’s filings and reports ~~filed~~ with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. In addition, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority, including expectations about their therapeutic potential and benefits thereof. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Overview

Since our inception in 2006, we have devoted substantially all our resources to research and development, raising capital, building our management team and building our intellectual property portfolio. To date, we have financed our

Table of Contents

operations primarily through ~~the sale~~sales of our common stock, Series A convertible preferred stock and warrants, ~~and convertible promissory notes. Through June 30, 2021, we raised an aggregate~~warrant exercises, the issuance of ~~$122.9 million from the sale of our Series A convertible preferred stock and warrants and~~ convertible promissory notes, and ~~in April 2020, we received a $0.5 million loan, or the PPP Loan, pursuant to~~ the Paycheck Protection Program orloan (“PPP loan”) that was forgiven in May 2021. In addition, in July 2020, the ~~PPP,~~Company entered into an Other Transaction Authority for Prototype Agreement (“OTA Agreement”), with the Department of Defense (“DoD”) to fund the Company’s efforts in developing an antibody cocktail therapeutic to treat COVID-19. The amount of funding available to the Company under this expense reimbursement contract was $13.3 million. In May 2021, the Company and the DoD amended the OTA Agreement, pursuant to which the DoD award was increased from $13.3 million to $17.6 million. As of June 30, 2022, the Company has received $17.4 million in expense reimbursement from the DoD under the ~~Coronavirus Aid, Relief, and Economic Security (CARES) Act implemented by~~OTA Agreement.

As of June 2022, the ~~U.S. Small Business Administration, which loan was forgiven on May 21, 2021.~~

On~~October 6, 2020, we closed the IPO,~~Company has transitioned into a clinical stage biopharmaceutical company as our Phase 1b study of IMM-BCP-01 in which we issued and sold 3,250,000 shares of our common stock at a public offering price of $12.00 per share. On October 13, 2020, the underwriters exercised their option to purchase an additional 487,500 shares of our common stock at a purchase price of $12.00 per share. We received net proceeds of $41.7 million after deducting underwriting discounts and commissions of $3.1 million but before deducting other offering expenses. On April 28, 2021, we sold 1,000,000 units, each comprising one share of our common stock and one warrant for one-half a share of common stock in a private placement and at a price of $27.00 per share for net proceeds of $26.4 million. In July 2021, we announced that our three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against thepatients infected with SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which we expect will enable viral clearance.

~~We are a development stage company, and all our programs are in a preclinical stage of development.~~is underway. To date, we have not generated any revenue from product sales and do not expect to generate revenue from the sale of products for the foreseeable future. Since inception we have incurred significant operating losses. Our net losses for the three months ended June 30, 2022 and 2021 ~~and 2020~~ were ~~$5.2~~$8.9 million and ~~$2.7~~$5.2 million, respectively, and ~~$9.1~~$20.6 million and ~~$5.4~~$9.1 million for the six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, respectively.

As of June 30, ~~2021,~~2022, we had a cash balance of ~~$59.8~~$34.6 million. We expect to continue to incur losses for the foreseeable future. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing research and development activities related to our portfolio of programs as we continue our preclinical and clinical development of ~~product candidates; advance these~~our product candidates ~~toward clinical development; further develop our product candidates;~~for IMM-ONC-01 and IMM-BCP-01, respectively. We also plan to perform research activities as we seek to discover and develop additional product candidates; carry out maintenance, expansion, enforcement, defense, and protection of our intellectual property portfolio; and hire research and development, clinical and ~~commercial~~administrative personnel. If we cannot obtain the necessary funding on favorable terms, if at all, we will need to delay, scale back or eliminate some or all of our research and development ~~programs or enter into collaborations with third parties~~programs. We may also need to ~~commercialize potential products or technologies that we might otherwise seek to develop or commercialize independently;~~ consider other various strategic alternatives, including a merger or sale of the Company; or reduce or cease operations. If we engage in collaborations, we may receive lower consideration upon commercialization of such products or technologies than if we had not entered into such arrangements or if we entered into such arrangements at later stages in the ~~product~~research and development process. We currently have no sources of revenue, and our ability to continue ~~as a going concern~~to fund our future business plans is dependent on our ability to raise capital to fund our present and future business plans. Additionally, volatility in the capital markets, the competitive landscape and general economic conditions in the United States may be a significant obstacle to raising the required funds.

~~Table of Contents~~

We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing ~~research and~~ development activities, particularly if and as we:

●

continue research and development activities, including pre-clinical and ~~preclinical studies;~~clinical development;

●

~~commence clinical trials~~pursue regulatory approvals and implement other regulatory strategies for our current and future product candidates;

●

take additional steps to advance ~~the development of~~our discovery engine and our existing and future pipeline;

●

obtain, maintain, expand and protect our intellectual property portfolio;

●

hire additional research and development, clinical ~~commercial~~ and administrative personnel;

●

~~pursue regulatory approvals~~scale up and ~~implement other regulatory strategies for our current and future product candidates;~~

●

~~scale up~~expand our clinical and regulatory capabilities; and

●

add operational, financial and management information systems and infrastructure to support our research and development programs, and any future commercialization efforts.

~~Furthermore, we expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.~~

As a result of these anticipated expenditures and potential unanticipated expenditures, we will need substantial additional financing to support our continuing operations and pursue our growth strategy. Until such time as we ~~can~~ generate

Table of Contents

significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of any stockholder will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.

Through June 30, 2022, we raised an aggregate of $125.1 million in gross proceeds from sales of our common stock, Series A convertible preferred stock and warrants, warrant and stock option exercises, the issuance of convertible promissory notes, and the PPP loan. On October 1, 2021, we entered into an Open Market Sale Agreement (“ATM Agreement”) with Jefferies Group LLC, which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell common shares having an aggregate offering price of up to $75.0 million through Jefferies Group LLC acting as sales agent. The Company has not yet sold any shares under the ATM Agreement.

We expect that our cash as of June 30, ~~2021~~2022 will be sufficient to fund our operations ~~through fiscal year 2022, and fund~~at least 12 months from the filing date of this Quarterly Report on Form 10-Q, including our planned Phase 1b studies for ~~IMM-ONC-01~~IMM-BCP-01 and ~~IMM-BCP-01.~~IMM-ONC-01. We have based these estimates on assumptions that may prove to be imprecise, and we may exhaust our available capital resources sooner than we currently expect. See “— Liquidity and capital resources.” Due to the numerous risks and uncertainties associated with the research and development of our programs, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.

Our Lead Discovery Programs

SARS-CoV-2 (“IMM-BCP-01”)

We are actively developing an antibody cocktail, comprising a combination of three effective anti-viral antibodies derived from the B cells of COVID-19 ~~Pandemic~~

patients that exhibit high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2 which include highly conserved, subdominant epitopes. The ~~ongoing~~cocktail promotes both ACE2 and non-ACE2 dependent neutralization and induces natural viral clearance mechanisms such as antibody dependent cellular cytotoxicity, complement activation and phagocytosis in pre-clinical testing. If successful in clinical testing, we expect that our antibody cocktail product candidate could be used both as a treatment for individuals who have contracted SARS-CoV-2 and as a prophylactic to offer protection against the virus for individuals who are at risk of contracting SARS-CoV-2. We are conducting this program in collaboration with the DoD, which has asserted that this platform may be of strategic importance, due to its potential use in the current COVID-19 pandemic ~~will continue to impact our projected research and development timelines~~as well as in future viral outbreaks. The IMM-BCP-01 program is broadly focused on the emerging variants of SARS-CoV-2. IMM-BCP-01 retains neutralization activity, in preclinical testing, against the Omicron variant and its ~~effect on~~sub-lineages, including the BA.4/.5 variants, which account for the majority of current cases. We submitted an IND application for the IMM-BCP-01 program to the U.S. FDA in November 2021. Following a brief clinical hold, the U.S. FDA communicated that the clinical study can be initiated for our ~~activities~~antibody cocktail for the treatment of SARS-CoV-2. Our Phase 1b study of IMM-BCP-01 in patients infected with SARS-CoV-2 is ~~uncertain.~~underway with topline data expected in the second half of 2022.

1820

Table of Contents

Oncology (“IMM-ONC-01”)

Our lead oncology program is focused on IL-38, which we believe is a novel, negative regulator of inflammation capable of promoting tumor evasion of the immune system. IL-38 was identified as the target of an antibody isolated from a hybridoma library generated from the memory B cells of a patient with squamous head and neck cancer. Query of public and proprietary databases of cancer gene expression revealed over-expression of IL-38 in multiple solid tumors. Further, a correlation with low levels of tumor-infiltrating immune effector cells, a hallmark of immune suppression in some of these patients’ tumors, and high IL-38 expression was also observed, suggesting a role for IL-38 as an immune checkpoint. Data obtained from preclinical testing indicated that blocking IL-38 function using inhibitory antibodies increased the immune response to the tumor and resulted in anti-tumor activity in select animal models, suggesting that anti-IL-38 antibodies could have therapeutic utility as single agents or in combination with other therapeutic modalities. Our recent analysis further confirms IL-38 expression is frequently elevated in samples of select patient tumor subtypes, in cancers such as head and neck, lung and gastroesophageal. We believe that this information could potentially guide patient selection for early clinical testing and may improve overall probability of demonstrating clinical utility, thereby improving the probability of clinical success. We plan to submit our IND application for the IMM-ONC-01 program in the second half of 2022.

Other Programs and Platform

In addition to the already described lead discovery programs, we will continue to invest in our proprietary discovery engine to expand our pipeline. The high output of antibody-target pairs resulting from our discovery engine may provide us with additional insights into the immune response against cancer and infectious diseases. We intend to continue to invest in this platform, to evaluate novel antibody-target pairs and to develop a pipeline of antibody therapeutics as single agents or in combination with other therapeutics or technologies to yield product candidates, such as Antibody-Drug Conjugates (“ADCs”). We believe our discovery engine has the ability to advance one to two programs into IND-enabling studies per year.

We also intend to continue to explore additional strategic partnerships and collaborations to expand our opportunities and capabilities. We intend to continue to form strategic partnerships with government agencies and with other third parties to accelerate our research and development efforts, as exemplified by our other transaction authority for prototype agreement with the DoD related to COVID-19. The insights we obtain may also enable strategic partnerships with other entities, including pharmaceutical and biotechnology companies. We also intend to continue collaborating with various vendors, manufacturers, and other service providers to complement the capabilities needed to continue to develop and commercialize our products.

Additionally, we plan to expand our intellectual property estate and infrastructure needed to discover and advance our platform and product candidates. We may in-license or acquire complementary intellectual property as needed or required, and we may continue to build our know-how and trade secrets. We may pursue both therapeutic and diagnostic applications of our antibodies through composition of matter and/or method of use patents. While our initial focus areas are in oncology and infectious disease, we may invest in intellectual property in other therapeutic areas as well.

COVID-19 Pandemic

In response to the COVID-19 pandemic, we have taken, and continue to take, proactive measures to prioritize health and safety, including of our employees and other personnel. These measures included establishing a work-from-home policy for our employees, other than those performing or supporting business-critical operations and implementing stringent safety measures designed to comply with applicable federal, state and local ~~guidelines instituted in response to the COVID-19 pandemic.~~guidelines. We have ~~begun to implement~~successfully implemented a back-to-work policy; our approach to transitioning back to the office iswas tailored to the role of each team member and evolves as the specific conditions associated with the COVID-19 pandemic continue to evolve. We will continue to monitor guidance and regulations from the Centers for Disease Control and local health authorities and will adjust our onsite rules and policies in accordance with this guidance and regulations.

We have also taken, and continue to take, proactive measures to maintain business continuity in the face of the COVID-19 pandemic. Communication throughout our organization has remained active during the pandemic. In

Table of Contents

addition, as part of our vendor management processes, we have ongoing dialogues with third-party service providers, which are intended to ensure that they continue to meet our criteria for business continuity.

The effect of the ongoing COVID-19 pandemic on our projected research and development timelines and activities is uncertain. Notwithstanding the measures taken, the future impact of COVID-19, including its variants, on our industry, the healthcare system and our current and future operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, including increases in inflation, supply chain disruption, labor shortage and shifting demand, among others. See “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March ~~25, 2021~~28, 2022 and elsewhere in our filings with the SEC for a discussion of the potential adverse impact of COVID-19 on our business, results of operations and financial condition.

Components of our results of operations

Research and development expenses

Research and development expenses consist of costs incurred in performing research and development activities, which include:

●

personnel-related expenses, including salaries, bonuses, benefits and share-based compensation for employees engaged in research and development functions;

●

expenses incurred in connection with the advancement of our programs, including under agreements with consultants, contractors, contract research organizations and other third-party vendors and suppliers;

●

expenses to conduct clinical trials including regulatory and quality assurance;

●

the cost of developing and validating our ~~quality and~~ manufacturing process for use in our preclinical studies and ~~potential future~~ clinical trials;

●

laboratory supplies and research materials and other infrastructure-related expenses; and

●

facilities, depreciation and amortization and other expenses which include direct and allocated expenses.

We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.

Research and development activities are central to our business model. We expect that our research and development expenses will increase substantially in connection with our planned preclinical and ~~future~~ clinical development activities.

In July 2020, we entered into ~~an Other Transaction Authority for Prototype~~the OTA Agreement ~~(the DoD Agreement)~~ with the DoD to fund our efforts in developing Biosynthetic Convalescent Plasma ~~(BCP)~~(“BCP”) to treat COVID-19. The OTA Agreement was modified in May 2021 to increase such funding. In connection

~~Table of Contents~~

with the ~~DoD~~OTA Agreement, we record expense reimbursements received from the DoD as contra-research and development expenses in the same period the underlying expenses are incurred.

Under the provisions of the CARES Act signed into law on March 27, 2020 and the subsequent extension of the CARES Act, the Company was deemed eligible to receive the employee retention credit subject to certain criteria. The Company recognized the employee retention credit as contra-expense to personnel related costs in research and development expenses in the condensed statements of operations.

Table of Contents

General and administrative expenses

General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation for personnel in our executive, ~~intellectual property,~~ business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, direct and allocated facility related expenses and other operating costs.

We anticipate that our general and administrative expenses will increase in the future to support increased and progressed research and development activities. ~~We also expect~~

Under the provisions of the CARES Act signed into law on March 27, 2020 and the subsequent extension of the CARES Act, the Company was eligible for a refundable employee retention credit subject to ~~incur increased~~certain criteria. The Company recognized the employee retention credit as contra-expense to personnel related costs ~~associated with being a public company, including costs~~in general and administrative expenses in the condensed statements of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance costs and investor and public relations costs.operations.

Interest income (expense), net

Interest income (expense), net consists of interest expense related to ~~our capital lease obligations and equipment~~ loans payable, offset by interest income earned on our cash.

Results of operations

The ultimate extent of the impact of any epidemic, pandemic, outbreak, or other public health crisis on our results of operations will depend on future developments, which are highly uncertain, including new information that may emerge concerning the severity of COVID-19 and its variants or other public health crisis and actions taken to contain or prevent the further spread, among others. Accordingly, we cannot fully predict the extent to which our business and results of operations will be ~~affected. For example, many clinical trial sites have been impacted~~affected by the ~~pandemic, forcing them to delay enrollment in trials and it is unclear for how long this will last. This may therefore impact our ability to commence clinical trials in the future.~~pandemic.

Comparison of the three and six months ended June 30, ~~2021~~2022 and ~~2020~~2021

Three Months Ended June 30,

Six Months Ended June 30

2021

2020

Change

2021

2020

Change

Operating expenses:

(in thousands)

(in thousands)
Research and development

$
3,233

$
1,892

$
1,341

$
5,212

$
4,007

$
1,205
General and administrative

2,507

823

1,684

4,425

1,363

3,062
Total operating expenses

5,740

2,715

3,025

9,637

5,370

4,267
Loss from operations

(5,740)

(2,715)

(3,025)

(9,637)

(5,370)

(4,267)
Other income

500

—

500

500

—

500
Interest income (expense), net

(1)

5

(6)

(2)

(17)

15
Net loss

$
(5,241)

$
(2,710)

$
(2,531)

$
(9,139)

$
(5,387)

$
(3,752)


	Three Months Ended June 30,						Six Months Ended June 30,
	2022		2021		Change		2022		2021		Change

Operating expenses:	(in thousands)						(in thousands)
Research and development	$	5,717	$	3,233	$	2,484	$	13,795	$	5,212	$	8,583
General and administrative		3,209		2,507		702		6,785		4,425		2,360
Total operating expenses		8,926		5,740		3,186		20,580		9,637		10,943
Loss from operations		(8,926)		(5,740)		(3,186)		(20,580)		(9,637)		(10,943)
Other income		—		500		(500)		—		500		(500)
Interest income (expense), net		2		(1)		3		3		(2)		5
Net loss	$	(8,924)	$	(5,241)	$	(3,683)	$	(20,577)	$	(9,139)	$	(11,438)

Three months ended June 30, 2022 and 2021

Research and development expenses

Research and development expenses were $5.7 million and $3.2 million, net of DoD reimbursement for the three months ended June 30, 2022 and ~~$1.9~~2021, respectively.

Research and development expenses increased by $2.5 million for the three months ended June 30, ~~2021 and 2020, respectively. Research~~2022. This increase is primarily due to a $4.1 million reduction of contra-research and development expense as a result of a reduction in BCP-01 program spending and reimbursable related expenses ~~for~~under the DoD agreement during the three months ended June 30, ~~2021 reflect the recognition of contra-research~~2022. Contra-research and development expenses ~~related to the DoD Agreement in the amount of $4.1 million, which off-sets~~offsets the expenses recognized in the period ~~for the DoD Agreement. Other non-DoD related research and development expenses increased $5.4 million for the three months ended June 30, 2021. This increase was primarily the~~

2023

Table of Contents

~~result of an increase of $4.3~~for the DoD Agreement. Personnel-related costs increased by $0.2 million ~~in supplies and outsourced services for other research and development activities and an increase of $1.0 million in personnel-related costs~~ due to an increase in headcount and stock-based compensation. These increases in personnel-related costs were offset by $0.6 million in contra-expense to personnel related costs relating to the CARES Act employee retention credit. In addition, outsourced research and raw materials decreased by $1.1 million and facility related costs decreased by $0.1 million for the three months ended June 30, 2022.

Research and development expenses are expected to increase in the future as we continue our current research programs, initiate new research programs, continue our preclinical development of product candidates and conduct current and future clinical trials for ~~any of~~ our programs and product candidates.

General and administrative expenses

General and administrative expenses increased by ~~$1.7~~$0.7 million to $3.2 million for the three months ended June 30, 2022 from $2.5 million for the three months ended June 30, ~~2021 from $0.8 million for the three months ended June 30, 2020.~~2021. The increase was primarily a result of ~~a $0.8~~$0.9 million increase in personnel-related costs due to an increase in headcount and stock-based compensation ~~and a $0.7 million increase in professional fees, consulting services, insurance and legal expenses to support our operations as a public company, and a~~offset by $0.2 million ~~increase~~ in ~~facility-related costs.~~

~~Other income~~

~~Other income consists of forgiveness of~~contra-expense to personnel related costs relating to the ~~PPP Loan. Other income increased $0.5 million for the three months ended June 30, 2021 from $0 in the prior year period.~~CARES Act employee retention credit.

Interest income (expense), net

Interest expense consists of interest related to ~~our capital lease obligations,~~ equipment loan ~~payables and long-term debt.~~payables. Interest income consists of interest earned on our cash balances held with financial institutions. ~~We recognized interest~~

Other income ~~net of expense, during~~

Other income for the three months ended June 30, 2021 consists of ~~$1,000 and attributable to~~forgiveness of the ~~increase in our cash balance from our April 2021 common stock offering. We recognized interest income $5,000, net of interest expense, during the three~~PPP Loan.

Six months ended June 30, ~~2020~~2022 and ~~attributable to the cash proceeds receive in connection with the sale of our Series A preferred stock.~~2021

~~Six Months Ended June 30, 2021~~

Research and development expenses

Research and development expenses were $13.8 million and $5.2 million, net of DoD reimbursement for the six months ended June 30, 2022 and ~~$4.0~~2021, respectively.

Research and development expenses increased by $8.6 million for the six months ended June 30, ~~2021 and 2020, respectively. Research~~2022. This increase is primarily due to a $7.4 million reduction of contra-research and development expense as a result of a reduction in BCP-01 program spending and reimbursable related expenses ~~for~~under the ~~six~~DoD agreement during the three months ended June 30, ~~2021 reflect the recognition of contra-research~~2022. Contra-research and development expenses ~~related to the DoD Agreement in the amount of $8.0 million, which off-sets~~offsets the expenses recognized in the period for the DoD Agreement. ~~Other non-DoD related research and development expenses~~Personnel-related costs increased ~~$9.3~~by $1.2 million for the six months ended June 30, 2021. This increase was primarily the result of a increase of $7.7 million in supplies and outsourced services for other research and development activities, an increase of $1.4 million in personnel-related costs due to an increase in headcount and stock-based ~~compensation,~~compensation. These increases in personnel-related costs were offset by $0.6 million in contra-expense to personnel related costs relating to the CARES Act employee retention credit. In addition, outsourced research and ~~an increase of~~raw materials increased by $0.8 million offset by $0.2 million decrease in ~~facility-related~~facility related costs.

General and administrative expenses

General and administrative expenses increased by ~~$3.1~~$2.4 million to ~~$4.4~~$6.8 million for the six months ended June 30, ~~2021~~2022 from ~~$1.3~~$4.4 million for the ~~six~~three months ended June 30, ~~2020.~~2021. The increase was primarily a result of a ~~$1.0~~$2.3 million increase in personnel-related costs due to an increase in headcount and stock-based compensation ~~and a $1.7~~offset by $0.2 million ~~increase~~ in contra-expense to personnel related costs relating to the CARES Act employee retention credit. In addition, professional fees ~~consulting services, insurance~~ and ~~legal~~other general expenses ~~to support our operations as a public company, and a $0.2~~increased by $0.3 million ~~increase in facility-related costs.~~for the six months ended June 30, 2022.

2124

Table of Contents

~~Other~~Interest income (expense), net

~~Other~~Interest expense consists of interest related to equipment loan payables. Interest income consists of ~~forgiveness of the PPP Loan.~~ interest earned on our cash balances held with financial institutions.

Other income ~~increased $0.5 million~~

Other income for the six months ended June 30, 2021 ~~from $0 in~~consists of forgiveness of the ~~prior year period.~~

~~Interest income (expense), net~~

We recognized interest income, net of expense, of $2,000 during the six months ended June 30, 2021 and attributable to the increase in our cash balance resulting from our April 2021 common stock offering. We recognized interest expense of $17,000, net of interest income, during the six months ended June 30, 2020 as a result of our capital lease obligations and equipment loans outstanding.PPP Loan.

Liquidity and capital resources

Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as ~~we advance the~~continue our preclinical ~~and, if successful, the clinical~~ development of product candidates and conduct current and future clinical trials for our ~~programs. To date, we have funded our operations primarily with proceeds from the sales of common stock, preferred stock and warrants, the convertible promissory notes and the PPP Loan.~~product candidates. Through June 30, ~~2021,~~2022, we raised an aggregate of ~~$122.9~~$125.1 million in gross proceeds from sales of our common stock, ~~and warrants,~~ Series A convertible preferred stock and warrants, warrant and stock option exercises, the issuance of convertible promissory notes, and the PPP ~~Loan.~~loan that was forgiven in May 2021. As of June 30, ~~2021,~~2022, we had ~~$59.8~~$34.6 million in cash. We filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 14, 2021, pursuant to which we may issue from time-to-time securities with an aggregate value of up to $200.0 million. In October 2021, we entered into an Open Market Sale Agreement (“ATM Agreement”) with Jefferies Group LLC, which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, we may elect, from time to time, to offer and sell common shares under the registration statement having an aggregate offering price of up to $75.0 million through Jefferies Group LLC acting as sales agent. We have not yet sold any shares under the ATM Agreement.

We will need to raise additional capital before we exhaust our current cash to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund ~~operations generally.~~operations. As and if necessary, we will seek to raise additional fundsthrough ~~various potential sources, such as~~a combination of equity ~~and~~offerings, debt financings, ~~or through corporate collaboration~~collaborations, strategic alliances and ~~license agreements.~~licensing arrangements. We can give no assurances that we will be able to secure such additional sources of funds to support our operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs.

Cash flows

The following table summarizes our sources and uses of cash for the six months ended June 30, ~~2021~~2022 and ~~2020:~~2021:

Six Months Ended June 30,


2021

2020


(in thousands)

Cash used in operating activities

$
(7,276)

$
(3,544)

Cash used in investing activities

(39)

(416)

Cash provided by financing activities

27,378

11,206

Net increase in cash and restricted cash

$
20,063

$
7,246


	Six Months Ended June 30,
	2022		2021

	(in thousands)
Cash used in operating activities	$	(14,436)	$	(7,276)
Cash used in investing activities		(176)		(39)
Cash provided by financing activities		32		27,378
Net increase (decrease) in cash and restricted cash	$	(14,580)	$	20,063

Operating activities

Net cash used in operating activities for the six months ended June 30, 2022 was $14.4 million, consisting primarily of our net loss of $20.6 million and decreases of accrued expenses and other liabilities of $3.3 million, offset by net noncash charges of $2.8 million for stock compensation expense, depreciation and amortization of right-of-use asset, decreases in prepaid expenses and other assets of $4.5 million, and increases in accounts payable of $2.2 million.

Net cash used in operating activities for the six months ended June 30, 2021 was $7.3 million, consisting primarily of our net loss of $9.1 million and forgiveness of the PPP loan of $0.5 million, offset by noncash charges of $1.4 million for stock compensation expense and depreciation and amortization, ~~of $0.4 million, and shared-based compensation of $1.1 million and an increase~~increases in accrued expenses and other liabilities of ~~$0.3 million and accounts payable of $0.5 million and a decrease in prepaid expenses and other assets of $0.1 million and increased by forgiveness of PPP Loan of $0.5 million.~~

Net cash used in operating activities for the six months ended June 30, 2020 was $3.5 million, consisting primarily of our net loss of $5.4 million, offset by noncash charges of depreciation and amortization expense $0.3 million and stock-based compensation of $0.2 million and increases in accounts payable and accrued expenses and other liabilities of $1.2 million due to our growth in expenditures and a decrease in prepaid expenses and other assets of $0.2 million.

2225

Table of Contents

$0.3 million, increases in accounts payable of $0.5 million, and decreases in prepaid expenses and other assets of $0.1 million.

Investing activities

During the six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, we used ~~$39,000~~$0.2 million and ~~$0.4~~$0.1 million, respectively, for the purchase of property and equipment.

Financing activities

During the six months ended June 30, 2022, financing activities provided $0.1 million from exercise of stock options.

During the six months ended June 30, 2021, financing activities provided $27.3 million from proceeds from the sale of common stock and common stock warrants, the exercise of common stock warrants and stock options, offset by the payment of issuance costs, and for payments related to our equipment loan.

During the six months ended June 30, 2020, financing activities provided $11.0 million from the sale of our Series A convertible preferred stock and warrants and $0.5 million from the PPP Loan, offset by $0.3 million for payments related to our capital lease obligations and equipment loan payables and $27,000 for the payment of issuance costs related to the sale of Series A convertible preferred stock and warrants.

Funding requirements

Our operating expenses are expected to increase substantially as we continue to advance our ~~portfolio of~~discovery engine and programs.

Specifically, our expenses will increase if and as we:

●

further develop our discovery engine;

●

continue our research and development programs for our current and any future product candidates from our current programs;

●

seek to identify additional research programs and additional product candidates;

●

~~initiate~~continue non-clinical testing and clinical ~~trials~~testing for our product candidates;

●

maintain, expand, enforce, defend, and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;

●

seek marketing approvals for any of our product candidates that successfully complete clinical trials;

●

~~ultimately~~ establish a sales, marketing, and distribution infrastructure to commercialize any medicines for which we may obtain marketing approval;

●

hire additional personnel including research and development, clinical and ~~commercial~~administrative personnel;

●

add operational, financial, and management information systems and personnel, including personnel to support our product development;

●

acquire or in-license products, intellectual property, and technologies; and

●

continue to operate as a public company.

We expect that our existing cash at June 30, ~~2021~~2022 will enable us to fund our current and planned operating expenses and capital expenditures ~~through fiscal year 2022. Beyond that~~at least 12 months from the filing date ~~the~~of this Quarterly Report on Form 10-Q. The Company will need additional financing to support its continuing operations and pursue its ~~growth~~development strategy. We have based

Table of Contents

these estimates on assumptions that may prove to be imprecise, and we may exhaust our available capital resources sooner that we currently expect. Because of the numerous risks and uncertainties associated with the development of our programs, we are unable to estimate the

~~Table of Contents~~

amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.

Our future funding requirements will depend on many factors including:

●

the costs of continuing to develop our discovery engine;

●

the costs of acquiring licenses, should we choose to do so, for the expansion of product development;

●

the scope, progress, results, and costs of discovery, preclinical development, laboratory testing, manufacturing and clinical trials for ~~the~~current and future product ~~candidates we may develop;~~candidates;

●

the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related ~~claims;~~claims and the success of our intellectual property portfolio;

●

the costs, timing, and outcome of regulatory review of the product candidates we may develop;

●

the costs of future activities, including product sales, medical affairs, marketing, manufacturing, distribution, coverage and reimbursement for any product candidates for which we receive regulatory approval;

●

the success of our ~~intellectual property portfolio;~~license agreements and our collaborations;

●

our ability to establish and maintain additional collaborations on favorable terms, if at all;

●

the achievement of milestones or occurrence of other developments that trigger payments under any additional collaboration agreements we obtain;

●

the extent to which we acquire or in-license products, intellectual property, and technologies; and

●

the costs of ~~continuing to operate~~operating as a public company.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of any purchaser will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Table of Contents

Critical accounting policies and use of estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United

~~Table of Contents~~

States. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our audited financial statements appearing in our Annual Report filed on Form 10-K with the SEC on March ~~25, 2021,~~28, 2022, we believe that the following accounting policies are the most critical to the judgments and estimates used in the preparation of our financial statements.

Share-based compensation

We recognize the grant-date fair value of share-based awards issued as compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the ~~estimated~~ fair value of the underlying common stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend ~~yield, the most critical of which is the estimated fair value of our common stock.~~yield.

The inputs and assumptions used to estimate the fair value of share-based payment awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different inputs and assumptions, our share-based compensation expense could be materially different for future awards.

~~These~~Expected volatility is a subjective ~~assumptions are estimated as follows:~~

●

~~Expected volatility.~~assumption that is estimated. The expected volatility was based on the historical stock volatility of several of our comparable publicly traded companies over a period of time equal to the expected term of the options, as we do not have sufficient trading history to use the volatility of our own common stock.

●

Fair value of common stock. On October 2, 2020, we closed our IPO. Following the closing, the fair value of common stock was the closing price of our common stock on the Nasdaq Global Market as reported on the date of the grant. Prior to that, our common stock had not historically been publicly traded and we had to periodically estimate the fair value of common stock.

~~Estimating the fair value of common stock~~

Prior to May 2020, in valuing our common and preferred stock, we determined the equity value of our business by using a net asset approach. The net asset approach is predicated on the assumption that a prudent buyer would pay no more than it would cost to purchase the assets (tangible and intangible) of a company at current market prices. This approach requires estimating the individual market values of our assets and liabilities to derive an adjusted enterprise value. The enterprise values determined by the net asset approach were then allocated to our common stock using the Option Pricing Method, or OPM.

~~The OPM treats common stock and preferred stock as call options on a company’s enterprise value, with exercise prices~~ based on the ~~liquidation preferences~~historical stock volatility of ~~the preferred stock. Therefore, the common stock has value only if the funds available for distribution to the stockholders exceed the value~~several of ~~the liquidation preference at the~~our comparable publicly traded companies over a period of time ~~of an assumed liquidity event such as a merger, sale or initial public offering. The common stock is modeled as a call option with a claim on the enterprise at an exercise price~~ equal to the ~~remaining value immediately after the preferred stock is liquidated. The OPM uses the Black-Scholes option-pricing model to determine the price~~expected term of the ~~call option.~~options, as we do not have sufficient trading history to use the volatility of our own common stock.

Accrued research and development expenses

As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders and communicating with personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The ~~OPM is~~majority of our service providers invoice us on a pre-determined schedule or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

Recently Adopted Accounting Standards

On January 1, 2022, the Company adopted Accounting Standards Update No. 2016-02, Leases (“Topic 842”) (“ASU 2016-02”), which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840. The standard generally requires lessees to recognize operating and finance lease liabilities and corresponding right-of-use

2528

Table of Contents

~~appropriate~~(“ROU”) assets on the balance sheet and provide enhanced disclosures on the amount, timing, and uncertainty of cash flows arising from lease arrangements. The Company adopted ASC 842 using the modified retrospective approach. The Company elected the package of practical expedients available for existing contracts, which allowed the Company to ~~use when~~carry forward our historical assessments of lease identification, lease classification, and initial direct costs. The Company also elected a policy to not apply the ~~range~~recognition requirements of ~~possible future outcomes is so difficult~~ASC 842 for short-term leases with a term of 12 months of less.

As of January 1, 2022, the effective date, the Company identified one operating lease arrangement relating to ~~predict that forecasts would be highly speculative.~~

~~Beginning~~the Company’s headquarter facility and a short-term lease relating to laboratory equipment. The adoption of ASC 842 resulted in ~~May 2020, we used the probability-weighted expected return method to determine the value of our common stock. Under the probability-weighted expected return method, the value~~a recognition of an ~~enterprise’s common stock is estimated based upon an analysis~~ROU asset and lease liability of ~~future values assuming various possible future liquidity events, such~~$0.2 million on the Company’s balance sheet relating to the leases as ~~an initial public offering, a strategic sale or merger and remaining a private enterprise without a liquidity event.~~of January 1, 2022. The ~~fair market value~~adoption of the ~~stock is based upon~~standard did not have a material effect on the ~~probability-weighted present value~~Company’s condensed statements of ~~expected future net~~operations and condensed statements of cash ~~flows as~~flows.

Recently Issued Accounting Pronouncements

In November 2021, the FASB issued ASU Topic 832, Disclosures by Business Entities about Government Assistance (“Topic 832”). This standard requires annual disclosures about transactions with a ~~result~~government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about the types of ~~distributions to stockholders considering each~~transactions, the accounting for the transactions, and the effect of the ~~possible future events, as well as~~transactions on an entity’s financial statements. The effective date of Topic 832 is for financial statements issued for annual periods beginning after December 15, 2021. The Company is currently evaluating the ~~rights~~effect Topic 832 will have on its financial statements and ~~preferences of each class of stock.~~

Given the absence of a public trading market for our capital stock at the time, our board of directors exercised reasonable judgment and considered a number of subjective factors to determine the best estimate of the fair value of our common stock, including:

●

~~our business, financial condition and results of operations, including related industry trends affecting our operations;~~

●

~~the likelihood of achieving a liquidity event, such as an initial public offering or the sale of the Company, given prevailing market conditions;~~

●

~~the lack of marketability of our preferred and common stock;~~

●

~~the market performance of comparable publicly traded companies; and~~

●

~~United States and global economic and capital market conditions and outlook.~~

~~Recently issued accounting standards~~

~~There are currently no recently issued accounting standards which management expects will impact the Company’s financial position, operations or cash flows.~~related disclosures.

JOBS Act

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of ~~this~~our initial public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.07 billion in annual revenue, we have more than $700.0 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K) or we issue more than $1.0 billion of non-convertible debt securities over a three-year period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have

~~Table of Contents~~

elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies.

~~Off-balance sheet arrangements~~

~~During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.~~

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The information under this item is not required to be provided by smaller reporting companies.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of ~~the end of~~ June 30, ~~2021,~~2022, our disclosure controls and procedures ~~are not designed at a reasonable assurance level and are not~~were effective ~~due~~ to ensure the ~~material weaknesses described below.~~

~~Discussion~~timely disclosure of ~~Material Weaknesses~~

In connection with our preparation of our financial statements as of June 30, 2021 and December 31, 2020 and for the three and six months ended June 30, 2021 and 2020, we identified material weaknesses as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States)required information in our internal control over financial reporting. The material weaknesses relate to the design of our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

The material weaknesses that we identified related to the lack of review of journal entries, lack of timely and effective review of financial statement account balances and our lack of maintaining a sufficient complement of personnel commensurate with our accounting and reporting requirements.

~~Remediation Activities~~

We are currently in the process of remediating the material weaknesses and have taken and will continue to take steps that we believe will address the underlying causes of the material weaknesses. The remediation efforts include (i) implementing a monthly financial statement close process that includes formal review of financial statement account balances and journal entries, (ii) creating a disclosure committee consisting of key executives and accounting personnel who review the Company’s financial statements and related disclosures and (iii) hiring full time accounting and finance resources, including a Chief Financial Officer, Controller, Finance Manager, and a Staff Accountant. While significant progress has been made to enhance our internal control over financial reporting, we are still in the process of implementing, documenting, and testing these processes, procedures and controls. We will continue to devote significant time and attention to these remediation efforts. However, the material weaknesses cannot be considered remediated until

~~Table of Contents~~

~~the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.~~

Notwithstanding the material weaknesses, management has concluded that the financial statements included elsewhere in this Quarterly Report present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with GAAP.SEC filings.

Changes in Internal Control Over Financial Reporting

~~Other than as described above under “Remediation Activities,” there was no change~~No changes in our internal control over financial reporting ~~identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(f) of the Exchange Act that~~ occurred during the quarter ended June 30, ~~2021~~2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

~~Table of Contents~~

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business.

Item 1A. Risk Factors

The information under this item is not required to be provided by smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~See our Current Report on Form 8-K filed on April 20, 2021 for a description of our unregistered sale of common stock.~~

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

2930

Table of Contents

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No.		Description of Exhibit

3.1		Amended and Restated Certificate of Incorporation of Immunome, Inc. (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed October 6, 2020).

3.2 10.1*		Amended and Restated Bylaws of Immunome, Inc. (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed October 6, 2020).

~~4.1~~		~~Form of Series B Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on April 26, 2021).~~

~~10.1#~~		~~Employment Letter Agreement between the Company and Corleen M. Roche, effective April 19, 2021 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 20, 2021).~~

~~10.2~~		Securities Purchase Agreement by and among the Company and the Purchasers signatory thereto, dated April 26, 2021 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 26, 2021).

~~10.3~~		Engagement Letter, by and between the Company and Ladenburg Thalmann & Co. Inc., dated April 9, 2021, as amended by the Amendment No. 1 thereto, dated April 25, 2021 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on April 26, 2021).

~~10.4~~		Modification of Contract between the Company and the Department of Defense, United States of America, dated May 19, 2021 (portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv)) (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 20, 2021).

10.5*		~~Fourth Amendment to~~ Second Amended and Restated ~~Management Services Agreement, dated~~Non-Employee Director Compensation Policy, effective as of June ~~1, 2021, by and between the Company and Broadband Capital Partners LLC.~~15, 2022
		.

31.1*		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, ~~2021~~2022 filed in XBRL). The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed." The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.

104		Cover Page Interactive File (embedded within the Inline XBRL document).

*	Filed or furnished herewith.

# Management contracts or compensatory plans or arrangements

~~Management contracts or compensatory plans or arrangements~~

3031

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IMMUNOME, INC.
	(Registrant)

Date: August ~~16, 2021~~5, 2022	By:	/s/ Purnanand D. Sarma
	Name:	Purnanand D. Sarma, Ph. D.
	Title:	President and Chief Executive Officer
		(Principal Executive Officer)

Date: August ~~16, 2021~~5, 2022	By:	/s/ Corleen M. Roche
	Name:	Corleen M. Roche
	Title:	Chief Financial Officer
		(Principal Financial Officer)

3132


	June 30, 2021		December 31, 2020
Assets
Current assets:
Cash	$	59,829	$	39,766
Prepaid expenses and other current assets		2,986		3,128
Total current assets		62,815		42,894
Property and equipment, net		1,226		1,531
Restricted cash		100		100
Total assets	$	64,141	$	44,525
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		1,790		1,187
Accrued expenses and other current liabilities		1,687		1,372
Equipment loan payable		44		113
Current portion of long-term debt		—		366
Total current liabilities		3,521		3,038
Long-term debt, net of current portion		—		134
Deferred rent		3		8
Total liabilities		3,524		3,180
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2021 and December 31, 2020; 11,812,792 shares issued and outstanding at June 30, 2021; 10,634,245 shares issued and outstanding at December 31, 2020		1		1
Additional paid-in capital		124,149		95,738
Accumulated deficit		(63,533)		(54,394)
Total stockholders’ equity		60,617		41,345
Total liabilities and stockholders’ equity	$	64,141	$	44,525


Years ending December 31,	Amount
2021 (represents remaining six months in 2021)	$	132
2022		153
	$	285


	Three Months Ended June 30,						Six Months Ended June 30
	2021		2020		Change		2021		2020		Change

Operating expenses:	(in thousands)						(in thousands)
Research and development	$	3,233	$	1,892	$	1,341	$	5,212	$	4,007	$	1,205
General and administrative		2,507		823		1,684		4,425		1,363		3,062
Total operating expenses		5,740		2,715		3,025		9,637		5,370		4,267
Loss from operations		(5,740)		(2,715)		(3,025)		(9,637)		(5,370)		(4,267)
Other income		500		—		500		500		—		500
Interest income (expense), net		(1)		5		(6)		(2)		(17)		15
Net loss	$	(5,241)	$	(2,710)	$	(2,531)	$	(9,139)	$	(5,387)	$	(3,752)